Castle Biosciences Inc (CSTL) Stock Price, Quote & News

Company Profile

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 866 788 9007

Website: castlebiosciences.com

Address:

505 S. Friendswood Drive, Suite 401, Friendswood, United States

OletaPinchback332 Feb. 21 at 6:42 AM

$CSTL Castle Biosciences provides diagnostic testing. Revenue growth depends on clinical adoption. Margins improve with scale.

0 · Reply

Flibenson Feb. 19 at 2:56 PM

$CSTL https://www.prnewswire.com/news-releases/merlin-cp-gep-becomes-the-first-and-only-gene-expression-profile-gep-test-recommended-by-nccn-cutaneous-melanoma-guidelines-to-assess-metastatic-risk-302692470.html

0 · Reply

Flibenson Feb. 19 at 2:47 PM

0 · Reply

ZacksResearch Feb. 18 at 2:49 PM

$NVO's Wegovy gets EC nod for higher dose — but is it enough to boost the stock? NVO shares down 9.9% in six months, lagging the industry’s 27.4% growth New 7.2 mg Wegovy dose shows promising weight loss results, yet the stock carries a Zacks Rank #5 (Strong Sell) Some better-ranked stocks are $HRMY, $ALKS, and $CSTL. Opportunity or risk? Full analysis here 👉 https://www.zacks.com/stock/news/2871232/eu-approves-novo-nordisks-higher-dose-wegovy-for-obesity-patients?cid=sm-stocktwits-2-2871232-body-33960&ADID=SYND_STOCKTWITS_TWEET_2_2871232_BODY_33960

0 · Reply

DonaldLefort773 Feb. 18 at 12:36 PM

$CSTL Diagnostics platform benefiting from preventative healthcare adoption; reimbursement stability is critical.

0 · Reply

commoncentsinvestor Feb. 6 at 5:53 PM

$CSTL ABEO selling for $5 with almost $4 in cash, new FDA approved Zevaskyn now on market. Going to fly.

0 · Reply

CapitalPilot Feb. 4 at 2:25 PM

$CSTL is a clinical-stage biotech developing cell therapies for cancer; it is a high-risk, early-stage company in the competitive cell therapy space.

1 · Reply

OfficialStocktwitsUser Jan. 28 at 8:58 PM

$CSTL RSI: 44.49, MACD: 0.8802 Vol: 1.31, MA20: 40.41, MA50: 39.19 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BioTechNoir Jan. 26 at 3:23 PM

$CSTL new 52 week

0 · Reply

SuperGreenToday Jan. 23 at 7:36 PM

$CSTL Share Price: $41.69 Contract Selected: Jul 17, 2026 $40 Calls Buy Zone: $5.10 – $6.30 Target Zone: $9.57 – $11.69 Potential Upside: 77% ROI Time to Expiration: 174 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

Feb 5, 2026, 7:00 AM EST - 18 days ago

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

Feb 4, 2026, 2:24 PM EST - 19 days ago

Allspring Emerging Growth Fund Q4 2025 Performance Review

AMSC ATGE ATI CORT CRS CVLT CWAN

Feb 4, 2026, 8:35 AM EST - 19 days ago

Wasatch Micro Cap Fund Q4 2025 Performance Review

AXGN BLZE CLMB MAMA VITL

Jan 11, 2026, 4:00 PM EST - 6 weeks ago

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

Dec 19, 2025, 7:00 AM EST - 2 months ago

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2025, 7:00 AM EST - 2 months ago

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

Dec 12, 2025, 7:00 AM EST - 2 months ago

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

Dec 9, 2025, 7:00 AM EST - 2 months ago

Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

Nov 17, 2025, 7:00 AM EST - 3 months ago

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

Nov 14, 2025, 7:00 AM EST - 3 months ago

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

Nov 11, 2025, 7:00 AM EST - 3 months ago

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 5, 2025, 8:02 AM EST - 3 months ago

Why Castle Biosciences' Rally Might Just Be Getting Started

Nov 3, 2025, 11:06 PM EST - 4 months ago

Castle Biosciences, Inc. (CSTL) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 4:07 PM EST - 4 months ago

Castle Biosciences Reports Third Quarter 2025 Results

Nov 3, 2025, 4:05 PM EST - 4 months ago

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

Oct 28, 2025, 7:00 AM EDT - 4 months ago

Castle Biosciences to Participate in Upcoming Investor Conferences

Oct 26, 2025, 3:05 PM EDT - 4 months ago

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett's Esophagus

Oct 24, 2025, 4:05 AM EDT - 4 months ago

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Oct 13, 2025, 7:00 AM EDT - 4 months ago

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

Oct 1, 2025, 4:30 PM EDT - 5 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

Sep 23, 2025, 7:00 AM EDT - 5 months ago

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award

Sep 17, 2025, 7:00 AM EDT - 5 months ago

Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025

Sep 9, 2025, 7:00 AM EDT - 6 months ago

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

Sep 2, 2025, 9:14 AM EDT - 6 months ago

Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential

Aug 25, 2025, 7:00 AM EDT - 6 months ago

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

Aug 4, 2025, 10:21 PM EDT - 7 months ago

Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 4:05 PM EDT - 7 months ago

Castle Biosciences Reports Second Quarter 2025 Results

Jul 29, 2025, 7:00 AM EDT - 7 months ago

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 25, 2025, 7:00 AM EDT - 7 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

Jul 23, 2025, 7:00 AM EDT - 7 months ago

FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma Test

Jul 17, 2025, 7:00 AM EDT - 7 months ago

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture

Jul 14, 2025, 7:00 AM EDT - 8 months ago

Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

Jun 16, 2025, 4:30 PM EDT - 9 months ago

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

Jun 11, 2025, 7:00 AM EDT - 9 months ago

Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention

Jun 4, 2025, 7:00 AM EDT - 9 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®

May 29, 2025, 4:30 PM EDT - 9 months ago

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

May 21, 2025, 7:00 AM EDT - 9 months ago

Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

May 9, 2025, 7:00 AM EDT - 10 months ago

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

May 7, 2025, 7:00 AM EDT - 10 months ago

Castle Biosciences Celebrates Skin Cancer Awareness Month

May 5, 2025, 10:58 PM EDT - 10 months ago

Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:06 PM EDT - 10 months ago

Castle Biosciences Reports First Quarter 2025 Results

May 5, 2025, 4:05 PM EDT - 10 months ago

Castle Biosciences to Acquire Previse

May 2, 2025, 4:30 PM EDT - 10 months ago

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

Apr 30, 2025, 5:00 PM EDT - 10 months ago

New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Apr 28, 2025, 7:00 AM EDT - 10 months ago

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

Apr 25, 2025, 4:15 PM EDT - 10 months ago

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

Apr 8, 2025, 7:00 AM EDT - 11 months ago

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

Apr 7, 2025, 7:00 AM EDT - 11 months ago

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

Apr 3, 2025, 7:00 AM EDT - 11 months ago

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test

OletaPinchback332 Feb. 21 at 6:42 AM

$CSTL Castle Biosciences provides diagnostic testing. Revenue growth depends on clinical adoption. Margins improve with scale.

0 · Reply

Flibenson Feb. 19 at 2:56 PM

0 · Reply

Flibenson Feb. 19 at 2:47 PM

0 · Reply

ZacksResearch Feb. 18 at 2:49 PM

0 · Reply

DonaldLefort773 Feb. 18 at 12:36 PM

$CSTL Diagnostics platform benefiting from preventative healthcare adoption; reimbursement stability is critical.

0 · Reply

commoncentsinvestor Feb. 6 at 5:53 PM

$CSTL ABEO selling for $5 with almost $4 in cash, new FDA approved Zevaskyn now on market. Going to fly.

0 · Reply

CapitalPilot Feb. 4 at 2:25 PM

$CSTL is a clinical-stage biotech developing cell therapies for cancer; it is a high-risk, early-stage company in the competitive cell therapy space.

1 · Reply

OfficialStocktwitsUser Jan. 28 at 8:58 PM

0 · Reply

BioTechNoir Jan. 26 at 3:23 PM

$CSTL new 52 week

0 · Reply

SuperGreenToday Jan. 23 at 7:36 PM

0 · Reply

BioTechNoir Jan. 22 at 3:27 PM

$CSTL new 52 week

0 · Reply

StockConsultant Jan. 16 at 6:11 PM

$CSTL Castle Biosciences stock, watch for a narrow range breakout at https://stockconsultant.com/?CSTL

0 · Reply

wiseman88 Jan. 13 at 2:41 PM

$CSTL preliminary reports show another strong quarter and finish to 2025. Expecting a good bump here until Feb earnings call.

0 · Reply

Quantumup Jan. 12 at 12:22 PM

Canaccord Genuity reiterated $CSTL Buy/$50: Here's what Canaccord Genuity had to say in its note to investors: https://x.com/Quantumup1/status/2010688023273341311?s=20

1 · Reply

OfficialStocktwitsUser Jan. 2 at 3:31 AM

$CSTL RSI: 56.79, MACD: 1.1543 Vol: 0.83, MA20: 39.19, MA50: 34.87 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

TradeTracs Dec. 30 at 12:54 AM

$CSTL - Strong recent earnings - Tight price action - Strong relative strength

0 · Reply

TradeTracs Dec. 26 at 6:44 PM

$CSTL - Strong sector and theme - Strong recent earnings - Tight price action

0 · Reply

CityCurator Dec. 26 at 12:22 PM

$CSTL Risk appetite is present but conditioned on validation. Cash efficiency must trend upward while maintaining strategic flexibility. Overextension would degrade optionality during downturns. Execution quality will determine whether momentum is sustainable.

0 · Reply

SpinDoctorStox Dec. 24 at 12:35 PM

$CSTL Market attention is shifting toward whether external catalysts materialize before balance-sheet pressure intensifies. Clear inflection points are required to justify renewed interest.

0 · Reply

BioTechNoir Dec. 22 at 6:30 PM

$CSTL screaming to $50+

0 · Reply

JarvisFlow Dec. 22 at 12:48 PM

Canaccord Genuity has updated their rating for Castle Biosciences ( $CSTL ) to Buy with a price target of 50.

0 · Reply

MichaelKTrades Dec. 18 at 9:56 PM

Market action is mixed IMO. Weaker inflation leads to further rate cuts and weaker USD $. May explain why silver and gold are hitting new highs. $GFI looks decent coming out of a multi week base. Other set ups for pilot buys if we rally $CSTL HTF $SGHT $PLTR

0 · Reply

Market Cap	852.61M
Revenue (ttm)	332.07M
Net Income (ttm)	18.25M
EPS (ttm)	N/A
PE Ratio	125.36
Forward PE	N/A
Profit Margin	5.50%
Debt to Equity Ratio	0.02

Volume	469,300
Avg Vol	388,262
Day's Range	N/A - N/A
Shares Out	29.19M
Stochastic %K	17%
Beta	1.06
Analysts	Strong Sell
Price Target	$48.12